US › Healthcare

X4 Pharmaceuticals Inc (XFOR)

US · Healthcare · Biotechnology

$3.50-0.28%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$8.8M

Revenue YoY

+346.3%

Net profit

$-16.2M

EPS

$-0.13

EPS estimate

$-0.19

Net margin

-183.5%

EPS came in at -0.13 against a street estimate of -0.19 — a beat of 31.6%.

Key statistics

Market cap

$347.0M

P/E

2.4

Forward P/E

0.0

P/B

2.17

Book value

$1.62

EPS (TTM)

$1.43

52-week high

$4.83

52-week low

$2.80

50-day MA

$4.03

200-day MA

$3.94

Beta

0.40

Analyst view

Analysts rate X4 Pharmaceuticals Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $11.60.

Shareholding

Insiders

0.44%

Institutions

100.14%

Largest institutional holders

Fund	Stake
Morgan Stanley - Brokerage Accounts	9.55%
FMR Inc	8.17%
Bain Capital Life Sciences Investors, LLC	8.04%
Kalehua Capital Management LLC	7.51%
Saturn V Capital Management LLC	7.03%
Empery Asset Management, LP	6.99%
Perceptive Advisors LLC	6.80%
Deep Track Capital, LP	5.93%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for X4 Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.